Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.

Drug Design, Development and Therapy
Kari E Roberts, Ioana R Preston

Abstract

Endothelin receptor antagonism has emerged as an important therapeutic approach in pulmonary arterial hypertension (PAH). Bench to bedside scientific research has clearly shown that endothelin-1 (ET-1) is over-expressed in several forms of pulmonary vascular disease and plays an important pathogenetic role in the development and progression of PAH. Oral endothelin receptor antagonists (ERAs) have been shown to improve exercise capacity, functional status, pulmonary hemodynamics, and delay the time to clinical worsening in several randomized placebo-controlled trials. Bosentan, the first oral ERA, was approved in 2001 and since that time it has established a strong record of safety and efficacy in PAH. More recently, two additional ERAs, ambrisentan and sitaxsentan, have been approved for use. The objective of this review is to evaluate the available evidence supporting the efficacy, pharmacology, safety and tolerability, and patient-focused perspectives for bosentan, the first approved ERA for PAH. Ongoing and forthcoming randomized trials are also highlighted including the application of bosentan in combination with other PAH therapies.

References

Sep 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·M YanagisawaK Goto
Jun 17, 1993·The New England Journal of Medicine·A GiaidD J Stewart
Jan 9, 1997·The New England Journal of Medicine·L J Rubin
Jan 31, 2002·American Journal of Respiratory and Critical Care Medicine·Neil DavieJohn Wharton
Mar 22, 2002·The New England Journal of Medicine·Lewis J RubinGerald Simonneau
Jan 11, 2003·Journal of Clinical Pharmacology·Paul L M van GiersbergenJasper Dingemanse
Sep 4, 2003·The European Respiratory Journal·M M HoeperE Spiekerkoetter
Jun 15, 2004·Journal of the American College of Cardiology·Gerald SimonneauAlfred Fishman
Jun 15, 2004·Journal of the American College of Cardiology·Marc HumbertMarlene Rabinovitch
Aug 20, 2004·American Journal of Respiratory and Critical Care Medicine·Olivier SitbonGérald Simonneau
Sep 11, 2004·The European Respiratory Journal·M HumbertG Simonneau
Dec 1, 2004·Clinical Pharmacokinetics·Jasper Dingemanse, Paul L M van Giersbergen
Feb 3, 2005·The European Respiratory Journal·V V McLaughlinL J Rubin
Mar 2, 2005·The European Respiratory Journal·M M HoeperJ Winkler
Jun 21, 2005·British Journal of Clinical Pharmacology·Gideon A PaulMartin R Wilkins
Mar 23, 2006·International Journal of Clinical Pharmacology and Therapeutics·P L M van GiersbergenJ Dingemanse
Jun 28, 2006·Circulation·Nazzareno GalièUNKNOWN Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators
Jul 22, 2006·Pediatric Research·Robert P JankovA Keith Tanswell
Sep 2, 2006·American Journal of Respiratory and Critical Care Medicine·Vallerie V McLaughlinLewis J Rubin
May 17, 2007·The European Respiratory Journal·M HumbertM M Hoeper
Nov 28, 2007·European Journal of Clinical Pharmacology·Gary BurgessJasper Dingemanse

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.